Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. Patients who were hospitalized for acute ...

Review the side-effects of Betrixaban as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The US Food and Drug Administration (FDA) has approved betrixaban (Bevyxxa, Portola Pharmaceuticals), an oral factor Xa inhibitor administered once daily, for the prevention of thromboembolic ...

Paul P. Dobesh, PharmD, explained that the approval of betrixaban was important for several reasons: VTE events continue to occur during hospitalization and following discharge, despite the standard ...

NEW ORLEANS, LA — Among patients hospitalized for acute medical illness, those who received the investigational new oral anticoagulant (NOAC) betrixaban (Portola) for about a month had fewer all-cause ...

Discover comprehensive details about Betrixaban, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Portola Pharmaceuticals has some work to do if it wants to see its oral factor Xa inhibitor betrixaban (Bevyxxa) approved for prevention of venous thromboembolism (VTE) in Europe, after a European ...

LONDON, UK — Although its trial setup may have caused complications, new research suggests that the new oral anticoagulant (NOAC) betrixaban (Portola Pharmaceuticals) may still be helpful in reducing ...

Portola Pharmaceuticals Inc. (NASDAQ: PTLA) revealed that the full results of its pivotal final stage APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) trial were presented ...

Extended use of betrixaban beyond the usual period of parenteral prophylaxis with enoxaparin reduced venous thromboembolism (VTE) incidence among medically ill patients. WASHINGTON, DC—Extended use of ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — In patients hospitalized for an acute medical illness, betrixaban, a novel Factor Xa inhibitor, ...

On Thursday, March 24, Portola announced the top-line results from APEX, a large phase 3 trial of the novel oral anticoagulant betrixaban. With two other Factor Xa inhibitors already on the market ...